Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B

The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naïve patients with HBeAg positive chronic hepatitis B. In this retrospective study, a total of 116 HBeAg positive patients, who received 30 mg of clevudine once daily (n=53) or...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kim, In Hee, Lee, Seok, Kim, Seong Hun, Kim, Sang Wook, Lee, Seung Ok, Lee, Soo Teik, Kim, Dae Ghon, Choi, Chang Soo, Kim, Haak Cheoul
Format: Artigo
Idioma:Inglês
Publicat: The Korean Academy of Medical Sciences 2010
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2858834/
https://ncbi.nlm.nih.gov/pubmed/20436711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2010.25.5.738
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars